共 39 条
- [1] Campo E(2011)The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications Blood 117 5019-5032
- [2] Kayser S(2011)The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML Blood 117 2137-2145
- [3] Shin SH(2013)Survival benefits with transplantation in secondary AML evolving from myelodysplastic syndrome with hypomethylating treatment failure Bone Marrow Transplant. 48 678-683
- [4] de Witte T(1995)Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatmen Leukemia 9 1805-1811
- [5] Hulegårdh E(2015)Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: A report from the Swedish Acute Leukemia Registry Am. J. Hematol. 90 208-214
- [6] Borthakur G(2009)Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia Cancer 115 3217-3221
- [7] Schoch C(2004)Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): An analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML Leukemia 18 120-125
- [8] Kern W(2018)Transplant outcomes for secondary acute myeloid leukemia: Acute Leukemia Working Party of the European Society for Blood and Bone Marrow Transplantation Study Biol. Blood Marrow Transplant. 24 1406-1414
- [9] Schnittger S(2018)Haploidentical transplantation outcomes for secondary acute myeloid leukemia: Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) study Am. J. Hematol. 93 769-777
- [10] Hiddemann W(2010)Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia J. Clin. Oncol. 28 2859-2867